EIF4G1 and hepatocellular carcinoma: Consistently, the combination of sorafenib with the eIF4E-eIF4G inhibitors 4E1RCat (structural) or 4EGI-1 (competitive) synergistically inhibits the cell viability and colony-formation ability of HCC cells [142].